PharmacoEconomics

, Volume 6, Issue 6, pp 513–522 | Cite as

The Costs of Rheumatoid Arthritis

  • Saralyn H. Allaire
  • Mark J. Prashker
  • Robert F. Meenan
Review Article Costs of Rheumatoid Arthritis

Abstract

Summary

The economic costs associated with rheumatoid arthritis (RA). a chronic. systemic. inflammatory disorder that affects many joints. are high. approximating those of coronary heart disease. The estimated prevalence of RA in the US is 0.9%. Incidence increases with age. and is highest among women in the fourth to sixth decades of life, The primary impact of RA is due to the significant morbidity associated with this disease. Mortality is increased among a poorly defined subgroup of RA patients. The average level of disability among RA patients is moderate. but 6.5 to 12% of patients are severely disabled. Between one- and two-thirds of prev iously employed patients have a reduced work capacity.

Treatment primarily involves the use of nonsteroidal anti -inflammatory drugs and disease modifying <lntirheumatic drugs. Rehabilitation measures and orthopaedic surgery are also used. Total annual direct costs of RA (total charges) have been calculated to be $US5275 and $US6099 ( 1991 dollars) per patient. Lifetime medical care charges were estimated at SUS 12578 per patient (1991 dollars).

The dircct costs of RA are substantial, but indirect costS have been calculated to be much higher because of extensive morbidity. The difference between the direct and indirect costs of RA is decreasing because salary increases have nOi kept pace with risin g heahhcare costs. The latter arc increasing rapidly in RA because of the use of new technology. surgical procedures. and the greater use of drugs with frequent monitoring requirements and significant toxicity. Because intangible costs such as pain form a substantial part of the overall costs ofRA but are difficult to evaluate. cost estimates inevitably underestimate the impact of the disease on individuals and society.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lubeck DP. Heahh care economics and policy. Curr Opin Rheumutol 1991; 3: 286–90CrossRefGoogle Scholar
  2. 2.
    Zvaiffer NJ. Rheumatoid arthritis: epidemiology, etiology, rheumatoid factor, pathology, pathogenesis. In: Shumacher HR, Klippel JH, Robinson DR, editors. Primer on the rheumatic diseases. Atlanta: Arthritis Foundation, 1988: 83-6Google Scholar
  3. 3.
    McCany DJ. Clinical picture of rheumatoid arthritis. In: McCany OJ, Koopman WJ, editors. Arthritis and allied conditions. Philadelphia: Lea & Febiger, 1993: 781–809Google Scholar
  4. 4.
    Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritic and mursculoskeletal diseases in the United States. J Rheumatol 1989; 16: 427–41PubMedGoogle Scholar
  5. 5.
    Ropes MW, Bennett GA, Cobb S, et al. 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 1958; 9: 175–6PubMedGoogle Scholar
  6. 6.
    Amett FC, Edworthy SM, Block DA, et al. The American Rheumatism Association 1987 revised crileria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–24CrossRefGoogle Scholar
  7. 7.
    Zvaiffer NJ. Etiology and pathogenesis of rheumatoid arthritis. In: McCany OJ, Koopman WJ, editors. Arthritis and allied conditions. Philadelphia: Lea & Febiger, 1993: 723–36Google Scholar
  8. 8.
    Epidemiology of the rheumatic diseases. In: McCany OJ, Koopman WJ, editors. Arthritis and allied conditions. Philadelphia: Lea & Febiger, 1993: 17–48Google Scholar
  9. 9.
    Pinals RS. Survival in rheumatoid arthritis. Arthritis Rheum 1981; 30: 473–5CrossRefGoogle Scholar
  10. 10.
    Milchell OM, Spilz PW, Young DY, et al. Survival, prognosis, and causes of death in rheumatoid arthritis. Anhriris Rheum 1986; 29: 706–14Google Scholar
  11. 11.
    Meenan RF, Kazis LE, Anderson JJ. The stability of health status in rheumatoid arthritis: a 5 year study of patients with established disease. Am J Public Health 1988; 78: 1484–7PubMedCrossRefGoogle Scholar
  12. 12.
    Sherrer YS, Bloch DA, Mitchell OM, et al. Disability in rheumatoid arthritis: comparison of prognostic factors across three populations. J Rheumalol 1987; 14: 705–9Google Scholar
  13. 13.
    Lichtenslein MJ, Pincus T. Rheumatoid arthristis, identified in population based cross sectional studies: low prevalence of rheumatoid factor. J Rheumatol 1991; 18: 989–93Google Scholar
  14. 14.
    Hochberg MC, Chang RW, Dwosh I, et al. The American College of Rheumalology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992; 35: 498–502PubMedCrossRefGoogle Scholar
  15. 15.
    Felts W, Yelin E. The economic impact of the rheumatic diseases in the United Slates. J Rheumatol 1989; 16: 867–84PubMedGoogle Scholar
  16. 16.
    Meenan RF, Yetin EH, Nevill M, et al. The impact of chronic disease: a sociomedical profile of rheumatoid arthritis. arthritis Rheum 1981; 24: 544–9PubMedCrossRefGoogle Scholar
  17. 17.
    Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mornality in seventy- five rheumatoid arthritis patients studied over nine years. Arthritis Rheum 1984; 27: 864–72PubMedCrossRefGoogle Scholar
  18. 18.
    Reisine ST, Grddy KE, Goodenow C, et al. Work disability among women with rheumatoid arthriris: Ihe relative importance of disease, social, work, and family factors. Arthritis Rheum 1989; 32: 538–43PubMedCrossRefGoogle Scholar
  19. 19.
    Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum 1987; 30: 507–12PubMedCrossRefGoogle Scholar
  20. 20.
    Makela M, Heliovaara M, Sievers K, et al. Musculoskeletal disorders as determinants of disability in Finns aged 30 years or more. J Clin Epidemiol 1993; 46: 549–59PubMedCrossRefGoogle Scholar
  21. 21.
    Jonsson B, Rehnberg C, Borgquist L, et al. Locomotion status and costs in destructive rheumatoid arthritis: a comprehensiive study of 82 patients from a population of 13,000. Acta Orthop Scand 1992; 63: 207–12PubMedCrossRefGoogle Scholar
  22. 22.
    Reisine ST, Goodcnow C, Grady KE. The impact of rheumatoid arthritis on the homemaker. Soc Sci Med 1987; 25: 89–95PubMedCrossRefGoogle Scholar
  23. 23.
    Allaire SH, Meenan RF, Anderwn JJ. The impact of rheumatoid arthritis on the household work performance of women. Arthritis Rheum 1991; 34: 669–78PubMedCrossRefGoogle Scholar
  24. 24.
    Yelin E, Luhed O, Holman H, et al. The impact of rheumatoid arthritis and osteoarthritis: the activities of patients with rheumatoid arthritis and osteoarthritis compared to controls. J Rheumatol 1987; 14: 710–7PubMedGoogle Scholar
  25. 25.
    Kolodny AL, Klipper A. Final report on the cost of treating arthritic disease: comparison between salicylates and non- salicylate nonsteroidal anti-intlammatory drugs. Am Arthritis Rheum 1985; 14 Suppl.1: 20–4CrossRefGoogle Scholar
  26. 26.
    Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastrupathy: incidence and risk factor models. Am J Med 1991; 91: 213–22PubMedCrossRefGoogle Scholar
  27. 27.
    Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am J Med 1988; 84 Suppl.2A: 20–4PubMedCrossRefGoogle Scholar
  28. 28.
    Jonnon B, Carlsson P. The effects of cimetidine on the cost of ulcer disease in Sweden. Soc Sci Med 1991; 33: 275–82CrossRefGoogle Scholar
  29. 29.
    Barradell LB, Whittington R, Benfield P. Misoprostol: pharmacoeconomics of its use as prophylaxis against gastruintestinal damage induced by nonsteroidal anti-intlammatory drugs. PharmacoEconomics 1993; 3: 140–170PubMedCrossRefGoogle Scholar
  30. 30.
    Prashler MJ. Health care research and policy studies. Curr Opin Rheum 1994; 6: 140–146CrossRefGoogle Scholar
  31. 31.
    Walt RP. Misoprostol for the treatment of peptic ulcer and anti-inflammatory-drug-induced gastroduodenal ulcerantion. N Engl J Med 1992; 327: 1575–80PubMedCrossRefGoogle Scholar
  32. 32.
    Roth S, Agrawal N, Mahowald M, et al. Misosprostol heals gastrointestinal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med 1989; 149: 775–779PubMedCrossRefGoogle Scholar
  33. 33.
    Henrihsofl K, Uribe A, Saoostedt B, et al. Helicobactor pylori infection. ABO blood group, and effect of misoprostol on gastroduodenal mucosa in NSAID-treated patients with rheumatoid arthritis. Dig Dis Sci 1990; 38: 1688–96Google Scholar
  34. 34.
    Downie WW. Diciofenac/misoprostol: A review of the major clinical trials evaluating its clinical efficacy and upper gastrointestinal tolerability in rheumatoid arthritis and osteoarthritis. Drugs 1993; 45 Suppl.1: 1–6PubMedCrossRefGoogle Scholar
  35. 35.
    Edelson JT, Tostesoo AN, Sax P. Cost-effectiveness of misoprolstol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastroimcs1inal bleeding. JAMA 1990; 264: 41–7PubMedCrossRefGoogle Scholar
  36. 36.
    Borg G, Allandcr E, Lund S, et al. Aurnnofin improves outcome in early rheumatoid arthritis: results from a 2-year, double- blind placebo controlled study. J Rheumatol 1988; 15: 1747–54PubMedGoogle Scholar
  37. 37.
    Felson D, Chernoff M, Wang M, et al. Does duration of disease affect patient response to second-line drugs in rheumatoid arthritis (RA)? [abstract] Arthritis Rheum 1993; 36 Suppl.: S178Google Scholar
  38. 38.
    Borg G, Allander E, Berg E, et al. Auranofin treatment in early rheumatoid arthritis may postpone early retirement: results from a 2-year double blind trial. J Rheumatol 1991; 18: 1015–20PubMedGoogle Scholar
  39. 39.
    Lorig KR, Mazonson PD, Holman HR. Evidence suggesting that health education for self-management in patients with chronic arthritis has sustained health benefits while reducing health care costs. Arthritis Rheum 1993; 36: 439–46PubMedCrossRefGoogle Scholar
  40. 40.
    Meenan RF, Yeelin EH, Henke CJ, et al. The costs of rheumatoid arthritis: a patient-oriented study of chronic disease costs. Arthritis Rheum 1978; 21: 827–33PubMedCrossRefGoogle Scholar
  41. 41.
    Prashker MJ, Cahill LA, Meenan RF. Rheumatology costs are increasing faster than intfation: results of a rheumatology cost of treatment index (RCTI) [abstract]. Arthritis Rheum 1993; 36 Suppl.: S65Google Scholar
  42. 42.
    Stone CE. The lifetime economic costs of rheumatoid arthritis. J Rheumatol 1984; 11: 819–27PubMedGoogle Scholar
  43. 43.
    Liang MH, Larson M, Thompson M, et al. Cost and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum 1984; 27: 522–9PubMedCrossRefGoogle Scholar
  44. 44.
    Lubeck DP, Spitz PW, Fries JF, et al. A multicenter study of annual health service utilization and cotS in rheumatoid arthritis. Arthritis Rheum 1986; 29: 488–93PubMedCrossRefGoogle Scholar
  45. 45.
    Jacobs J, Keyserling JA, Brilton M, et al. The tOtal cost of care and the use of pharmaceuticals in the managenment of rheumatoid arthritis: the Medi-Cal program. J Clin Epidemiol 1988; 41: 215–23PubMedCrossRefGoogle Scholar
  46. 46.
    Finkler SA. The distinction between cost and charges. Ann Intern Med 1982; 96: 102–9PubMedGoogle Scholar
  47. 47.
    Social and economic impacts of four musculoskeletal conditions: a study using national community-based data. Arthritis Rheum 1983; 26: 901–7Google Scholar
  48. 48.
    Prashker MJ, Meenan RF. The costs of drug therapy for rheumatoid arthritis. Arthritis Rheum 1992; 35 Suppl.: S45Google Scholar
  49. 49.
    Sorg G, Allander E, Goubar JE. Disease-modifying anti-rheumatic drug therapy: an uxtensive therapy despite inexpensive drugs. Scand J Rheumatol 1990; 19: 115–21CrossRefGoogle Scholar
  50. 50.
    Jajie I, Jajie Z, Ozic-Bebek M, et al. Socioeconomic aspects of rheumatoid arthritis [Serbo-Croat]. Reumatizam 1991; 38: 7/11/2012Google Scholar
  51. 51.
    Wolfe F, Klenheksel SM, Spitz PW, et al. A multicenter study of hospitalization rheumatoid arthritis: frequency, medical- surgical admissions, and charges. Arthritis Rheum 1986; 29: 614–9PubMedCrossRefGoogle Scholar
  52. 52.
    Quam JP, Michet Jr CJ, Wilson MG, et al. Total knee arthroplasty: a population-based study. Mayo Clin Proc 1991; 66: 589–95PubMedGoogle Scholar
  53. 53.
    Mellon U, Stauffer RN, Chao EYS, et al. Rates of total hip arthroplasty. N Engl J Med 1982; 307: 1242–5CrossRefGoogle Scholar
  54. 54.
    Jöonson B, Larsson SE. Functional improvement and costs of hip and knee arthroplasty in destructive rheumatoid arthritis. Scand J Rheumatol 1991; 20: 351–7CrossRefGoogle Scholar
  55. 55.
    Allaire SH, De Nardo BS, Szer LS, et al. The economic impacts of juvenile rheumatoid arthritis. J Rheumatol 1992; 19: 952–5PubMedGoogle Scholar
  56. 56.
    Mitchell JM, Burkhauser RV, Pincus T. The importance of age, education, and comorbidity in the substantial earnings losses of individuals with symmetric polyarthritis. Arthritis Rheum 1988; 31: 348–57PubMedCrossRefGoogle Scholar
  57. 57.
    Hudson JI, Hudson MS, Pliner LF, et al. Fibrotnyalgia and major affective disorder: a controlled phenomenology and family history study. Am J Psychiatry 1985; 142: 441–6PubMedGoogle Scholar
  58. 58.
    Rimon R, Laakso RL. Overt psychopathology in rheumatoid arthritis: a fifteen year follow-up study. Scand J Rheumatol 1984; 13: 324–8PubMedCrossRefGoogle Scholar
  59. 59.
    Frank RG, Beek NC, Parker JC, et al. Depression in RA. J Rheumatol 1988; 15: 920–5PubMedGoogle Scholar
  60. 60.
    McFarlane AC, Brooks PM. An analysis of the relationship between psychological morbidity and disease activity in RA. J Rheumatol 1988; 15: 926–31PubMedGoogle Scholar
  61. 61.
    Hawley DJ, Wolfe F. Anxiety and depression in patients With RA. J Rheumatol 1988; 15: 932–41PubMedGoogle Scholar
  62. 62.
    Beckham JC, D’Amico CJ, Rice JR, et al. Depression and level of functioning in patients with rheumatoid arthritis. Can J Psychiatry 1992; 37: 539–43PubMedGoogle Scholar
  63. 63.
    Devins GM, Edworthy SM, Guthrie NE, et al. Illness intrussiveness in rheumatoid arthritis: diffential impact depressive symptoms over the adult lifespan. J Rheumatol 1992; 19: 709–15PubMedGoogle Scholar
  64. 64.
    Devins GM, Edworthy SM, Seland TP, et al. Differences in illness in trusiveness across rheumatoid arthritis, end-stage renal disease, and multiple selerosis. J Nerv Ment Dis 1993; 181: 377–81PubMedCrossRefGoogle Scholar
  65. 65.
    Browne GB, Arpin K, Corey P, et al. Individual cOrrelates of health service utilization and the cost of poor adjustment to chronic illness. Med Care 1990; 28: 43–58PubMedCrossRefGoogle Scholar
  66. 66.
    Bell MJ, Bombardier C, Tugwell P. Measurement of functional status, quality of life, and utility in rheumatoid arthritis. Arthritis Rheum 1990; 33: 591–601PubMedCrossRefGoogle Scholar
  67. 67.
    Tugwell P, Bombardier C, Walson WW, et al. Metholtrexate in rheumatoid arthritis. Arch Intern Med 1990; 150: 59–62PubMedCrossRefGoogle Scholar
  68. 68.
    Thompson MS, Read JH, Hutchings HC, et al. The cost effectiveness of auranofin: results of a randomized clinical trial. J Rheumatol 1988; 15: 35–42PubMedGoogle Scholar
  69. 69.
    Thompson MS. Willingness to pay and accept risks tn cure chronic disease. Am J Public Health 1986; 76: 392–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1994

Authors and Affiliations

  • Saralyn H. Allaire
    • 1
  • Mark J. Prashker
    • 2
  • Robert F. Meenan
    • 3
  1. 1.Boston University Arthritis CenterBoston University School of MedicineBostonUSA
  2. 2.Boston Veterans Administration Medical CenterBostonUSA
  3. 3.School of Public HealthBoston UniversityBostonUSA

Personalised recommendations